BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20592382)

  • 21. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
    Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
    Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
    Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
    Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic role of the sentinel lymph node in clinically node-negative patients with cutaneous melanoma: experience of the Genoa group.
    Gipponi M; Solari N; Lionetto R; Di Somma C; Villa G; Schenone F; Queirolo P; Cafiero F
    Eur J Surg Oncol; 2005 Dec; 31(10):1191-7. PubMed ID: 15894454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
    Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
    Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sentinel node identification by scintigraphic methods in cutaneous melanoma.
    Dias Moreira R; Altino de Almeida S; Maliska Guimarães CM; Resende JF; Gutfilen B; Barbosa da Fonseca LM
    J Exp Clin Cancer Res; 2005 Jun; 24(2):181-5. PubMed ID: 16110749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sentinel lymph node biopsy in elderly irish patients with malignant melanoma.
    Moran DE; Smith MJ; O'Sullivan MJ; Bannon H; Crotty TB; Collins CD; Skehan SJ; O'Higgins N; McDermott EW; Evoy D; Hill AD
    Ir Med J; 2007 Apr; 100(4):422-4. PubMed ID: 17566474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sentinel lymph node biopsy in cutaneous melanoma: outcome after 5-years follow-up.
    Cuchet E; Pinel N; Corcella D; Vuillez JP; Lebeau J; Moutet F; Colonna M; Leccia MT
    Eur J Dermatol; 2007; 17(5):387-91. PubMed ID: 17673381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Serum levels of S-100b protein after four years follow-up of patients with melanoma].
    Zissimopoulos A; Karpouzis A; Karaitianos I; Baziotis N; Tselios I; Koutis C
    Hell J Nucl Med; 2006; 9(3):204-7. PubMed ID: 17160167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients.
    Scoggins CR; Martin RC; Ross MI; Edwards MJ; Reintgen DS; Urist MM; Gershenwald JE; Sussman JJ; Dirk Noyes R; Goydos JS; Beitsch PD; Ariyan S; Stromberg AJ; Hagendoorn LJ; McMasters KM
    Ann Surg Oncol; 2010 Mar; 17(3):709-17. PubMed ID: 19967459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria.
    van der Ploeg AP; van Akkooi AC; Schmitz PI; Koljenovic S; Verhoef C; Eggermont AM
    Eur J Cancer; 2010 Sep; 46(13):2414-21. PubMed ID: 20621467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review.
    Gipponi M; Di Somma C; Peressini A; Solari N; Gliori S; Nicolo G; Schenone F; Queirolo P; Sertoli MR; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):133-40. PubMed ID: 14991885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of the RT-PCR positive sentinel node in melanoma.
    Temple CL; Snell LJ; Power SM; Parfitt JR; Scilley C; Engel CJ; Shum D; Chakrabarti S; Joseph MG; Lohmann RC; Ainsworth P
    J Surg Oncol; 2007 Jun; 95(7):546-54. PubMed ID: 17219388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Results of the determination of serum markers in patients with malignant melanoma.
    Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
    Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival in sentinel lymph node-positive pediatric melanoma.
    Roaten JB; Partrick DA; Bensard D; Pearlman N; Gonzalez R; Fitzpatrick J; McCarter MD
    J Pediatr Surg; 2005 Jun; 40(6):988-92; discussion 992. PubMed ID: 15991183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].
    Arens A; Osinga J; Schwipper V; Schober O; Tilkorn H; Liebau J
    Chirurg; 2003 Jul; 74(7):665-70. PubMed ID: 12883795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.